.Pharmacolibrary.Drugs.R_RespiratorySystem.R03D_OtherSystemicDrugsForObstructiveAirwayDiseases.R03DX05_Omalizumab.Omalizumab .Pharmacolibrary.Drugs.R_RespiratorySystem.R03D_OtherSystemicDrugsForObstructiveAirwayDiseases.R03DX05_Omalizumab.Omalizumab| name: | Omalizumab |
| ATC code: | R03DX05 | route: | subcutaneous |
| n-compartments | 2 |
Omalizumab is a humanized monoclonal antibody that selectively binds to immunoglobulin E (IgE). It is primarily used as an add-on therapy for moderate to severe persistent allergic asthma not adequately controlled with inhaled corticosteroids. Omalizumab is also approved for treatment of chronic spontaneous urticaria. The drug is administered subcutaneously and is approved in the United States, Europe, and many other countries.
Population pharmacokinetics in adult and adolescent patients with moderate to severe allergic asthma after subcutaneous administration.
Luu, M, et al., & Goirand, F (2016). Pharmacokinetics, pharmacodynamics and clinical efficacy of omalizumab for the treatment of asthma. Expert opinion on drug metabolism & toxicology 12(12) 1503–1511. DOI:10.1080/17425255.2016.1248403 PUBMED:https://pubmed.ncbi.nlm.nih.gov/27748630
Plosker, GL, & Keam, SJ (2008). Omalizumab: a review of its use in the treatment of allergic asthma. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 22(3) 189–204. DOI:10.2165/00063030-200822030-00005 PUBMED:https://pubmed.ncbi.nlm.nih.gov/18481901
Lowe, PJ, et al., & Jimenez, P (2009). Relationship between omalizumab pharmacokinetics, IgE pharmacodynamics and symptoms in patients with severe persistent allergic (IgE-mediated) asthma. British journal of clinical pharmacology 68(1) 61–76. DOI:10.1111/j.1365-2125.2009.03401.x PUBMED:https://pubmed.ncbi.nlm.nih.gov/19660004